Praxis Precision Medicines, Inc. granted restricted stock unit awards to 6 new non-executive employees on December 1, 2025, under the 2024 Inducement Plan. The awards cover 3,594 shares of common stock and will vest in four equal annual installments. Praxis develops therapies for CNS disorders using genetic insights and proprietary platforms. The company focuses on rare and prevalent neurological disorders, with four clinical-stage product candidates. For more information, visit www.praxismedicines.com and follow Praxis on Facebook, LinkedIn, and Twitter.

Read more at GlobeNewswire: Praxis Precision Medicines, Inc. Announces Inducement